May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Reversible Regulation of Ocular Transgene Expression
Author Affiliations & Notes
  • P.A. Overbeek
    Dept of Mol. and Cell. Biology, Baylor College of Medicine, Houston, TX
  • W. Harrison
    Dept of Mol. and Cell. Biology, Baylor College of Medicine, Houston, TX
  • N. Xiao
    Dept of Mol. and Cell. Biology, Baylor College of Medicine, Houston, TX
  • D. Liang
    Dept of Mol. and Cell. Biology, Baylor College of Medicine, Houston, TX
  • V. Govindarajan
    Dept of Mol. and Cell. Biology, Baylor College of Medicine, Houston, TX
  • Footnotes
    Commercial Relationships  P.A. Overbeek, None; W. Harrison, None; N. Xiao, None; D. Liang, None; V. Govindarajan, None.
  • Footnotes
    Support  NIH Grants EY10803, EY10448
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3424. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.A. Overbeek, W. Harrison, N. Xiao, D. Liang, V. Govindarajan; Reversible Regulation of Ocular Transgene Expression . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3424.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: In order to study ocular responses to transgene expression, it would be advantageous to be able to regulate the timing and duration of transgene expression. Our goal is to establish a bigenic system for reversible regulation of transgene expression in the eye. Methods: Two different systems have been tested. One is based on the yeast Gal4 transcription factor. The other is based upon a recombinant tetracycline transactivator (tTA). Engineered versions of Gal4 and tTA were linked to ocular promoters (Pax–6 and DREAM) and used to generate transgenic mice. The regulatory elements that are bound by these transactivators (UAS and TRE, respectively) were linked to target transgenes including lacZ. These constructs were used to generate transgenic mice. Bigenic mice, generated by mating transactivator mice with responder mice, were assayed for expression of the target transgenes. Results: Five Pax6–Gal4 transgenic families were generated. In situ hybridization identified three families with good transgene expression in the lens and corneal epithelial cells. Six UAS–lacZ families were generated and mated to the Pax6–Gal4 mice. One UAS–lacZ family (OVE1977) showed no X–gal staining in the absence of Gal4. In bigenic mice, X–gal staining was detected in the eye beginning at embryonic day 10 (E10). This UAS–lacZ reporter family has been mated to mice that express a RU486–regulated version of Gal4 to establish the parameters for inducible and reversible lacZ expression. Six DREAM–tTA families have been generated, along with three TRE–lacZ families. Embryos (E11) that carry both of these transgenes show lens–specific staining with X–gal. Additional studies need to be done to establish the time course for induction and reversion of transgene expression in response to administration of RU486 or doxycycline. Conclusions: Both Gal4 and tTA can be used as transactivators for ocular–specific regulation of trangene expression. These transactivators can now be used for timed studies of signal transduction pathways, transcriptional responses, and cell morphology changes in response to induction or elimination of expression of specific transgenes.

Keywords: transgenics/knock–outs • gene/expression • signal transduction 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×